Toggle navigation
Home
Search
Services
Blog
Contact
About
Astatine-211 Labeled Antibodies for Therapy
Wilbur, D Scott
Neorx Corporation, Seattle, WA, United States
Search 444 grants from D Wilbur
Search grants from Neorx Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Defining Optimal Transitions of Care in Advanced Kidney Disease: Conservative Management vs. Dialysis Approaches
Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for Alzheimer's Disease
Vascular Smooth Muscle and Blood Pressure Regulation By Cyb5R3
Cruciferous Dithiolethiones for Chronic Heart Failure: Signaling Mechanisms
Pregnancy Risk Assessment Monitoring System (PRAMS)
Recently added grants:
Regulation of Rotavirus Replication, Virulence, and Host Range Restriction by the Innate Immune System
Administrative Core
CD4 T cell control of cytomegalovirus
Virology Core
Wisconsin Infant Study Cohort (WISC)
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Small Business Innovation Research – Phase I (N43)
Project #
N43CM067941-001
Application #
3614582
Study Section
Project Start
1986-09-24
Project End
Budget Start
1986-11-01
Budget End
1987-03-31
Support Year
Fiscal Year
1987
Total Cost
Indirect Cost
Institution
Name
Neorx Corporation
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98119
Related projects
NIH 1987
N43 CM
Astatine-211 Labeled Antibodies for Therapy
Wilbur, D Scott / Neorx Corporation
NIH 1986
N43 CM
Astatine-211 Labeled Antibodies for Therapy
Wilbur, D Scott / Neorx Corporation
Comments
Be the first to comment on this grant